Dextroamphetamine

Generic Name: Dextroamphetamine

Brand Names: Adderall, Dexedrine, Mydayis, Procentra, Xelstrym, Zenzedi

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N

CAS Number: 51-64-9

Unique Ingredient Identifier: TZ47U051FI

Background: Dextroamphetamine is the dextrorotary enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.

Indication: Dextroamphetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).

Associated Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Narcolepsy

Associated Therapies: -

Clinical Trials

A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users

Phase 1

Terminated

Conditions: Abuse Potential

Interventions: Drug: Placebo oral tablet
Drug: Tozadenant
Drug: Placebo oral capsule
Drug: d-amphetamine

First Posted Date: 2017-06-27

Last Posted Date: 2018-08-13

Lead Sponsor: Biotie Therapies Inc.

Target Recruit Count: 26

Registration Number: NCT03200080

Locations: 🇨🇦
INC Research Toronto, Inc., Toronto, Ontario, Canada

Targeting Anhedonia in Cocaine Use Disorder

Phase 2

Completed

Conditions: Cocaine-Related Disorders
Anhedonia

Interventions: Drug: d-amphetamine
Behavioral: Contingency management
Drug: Placebo (for d-amphetamine)

First Posted Date: 2016-05-16

Last Posted Date: 2024-08-09

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 57

Registration Number: NCT02773212

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

Dexamphetamine Sustained Release Pharmacokinetics and Clinical Validation of Dried Blood Spots

Early Phase 1

Completed

Conditions: Cocaine Addiction

Interventions: Drug: Dexamphetamine

First Posted Date: 2016-05-11

Last Posted Date: 2017-06-02

Lead Sponsor: The Netherlands Cancer Institute

Target Recruit Count: 12

Registration Number: NCT02768441

Locations: 🇳🇱
AMC, Amsterdam, Netherlands

Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Dextroamphetamine
Drug: Placebo

First Posted Date: 2015-12-18

Last Posted Date: 2021-08-17

Lead Sponsor: University of California, San Diego

Target Recruit Count: 82

Registration Number: NCT02634684

Locations: 🇺🇸
Clinical Teaching Facility (CTF-B102) at UCSD Medical Center, San Diego, California, United States

Dextroamphetamine and tDCS to Improve the Fluency

Phase 2

Completed

Conditions: Stroke

Interventions: Device: Active tDCS
Drug: Dexedrine
Behavioral: Speech Therapy
Device: Sham tDCS
Drug: Placebo

First Posted Date: 2015-08-03

Last Posted Date: 2018-08-03

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 10

Registration Number: NCT02514044

Locations: 🇺🇸
University of Texas Health Science Center, Houston, Texas, United States

D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement

Phase 2

Completed

Conditions: Pathological Gambling

Interventions: Drug: Haloperidol
Drug: Fluphenazine
Drug: Dexedrine
Drug: Placebo
Behavioral: Slot Machine

First Posted Date: 2014-07-30

Last Posted Date: 2016-04-25

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 60

Registration Number: NCT02203786

Locations: 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Amphetamine-Enhanced Stroke Recovery

Phase 2

Completed

Conditions: Stroke

Interventions: Drug: Dextroamphetamine
Other: Physical Therapy
Drug: Placebo

First Posted Date: 2013-07-23

Last Posted Date: 2013-07-23

Lead Sponsor: Duke University

Target Recruit Count: 99

Registration Number: NCT01905371

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Spectroscopic Imaging at 4T: A Drug Challenge Study

Not Applicable

Terminated

Conditions: AOD Effects and Consequences

Interventions: Other: Placebo
Drug: Alprazolam
Drug: Dextroamphetamine

First Posted Date: 2012-04-16

Last Posted Date: 2017-04-04

Lead Sponsor: Mclean Hospital

Target Recruit Count: 7

Registration Number: NCT01577706

Locations: 🇺🇸
McLean Imaging Center, McLean Hospital, Belmont, Massachusetts, United States

Comparing the Efficacy of Methylphenidate, Dextroamphetamine and Placebo in Children Diagnosed With ADHD

Phase 4

Completed

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Methylphenidate
Drug: Placebo
Drug: Dextroamphetamine

First Posted Date: 2010-10-14

Last Posted Date: 2010-10-14

Lead Sponsor: Ostfold Hospital Trust

Target Recruit Count: 36

Registration Number: NCT01220440

Locations: 🇳🇴
Ostfold Hospital Neuropsychiatric Unit, Fredrikstad, Ostfold, Norway
🇳🇴
Østfold Hospital Neuropsychiatric Unit, Fredrikstad, Østfold, Norway

Studying Amphetamine Withdrawal in Humans

Phase 2

Completed

Conditions: Methamphetamine Dependence

Interventions: Drug: Placebo
Drug: Dextroamphetamine

First Posted Date: 2010-10-07

Last Posted Date: 2014-08-04

Lead Sponsor: University of Arkansas

Target Recruit Count: 35

Registration Number: NCT01215929

Locations: 🇺🇸
University of Arkansas for Medical SCiences, Little Rock, Arkansas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy